Should I buy or sell Celcuity stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celcuity in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CELC shares. View CELC analyst ratings or view top-rated stocks .

What is Celcuity's stock price target for 2024?

4 Wall Street analysts have issued 1-year target prices for Celcuity's shares. Their CELC share price targets range from $24.00 to $40.00. On average, they anticipate the company's stock price to reach $29.00 in the next twelve months. This suggests a possible upside of 76.9% from the stock's current price. View analysts price targets for CELC or view top-rated stocks among Wall Street analysts .

How have CELC shares performed in 2024?

Celcuity's stock was trading at $14.57 at the beginning of 2024. Since then, CELC stock has increased by 12.5% and is now trading at $16.39. View the best growth stocks for 2024 here .

Are investors shorting Celcuity?

Celcuity saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 1,860,000 shares, a decrease of 7.5% from the March 15th total of 2,010,000 shares. Based on an average daily volume of 230,800 shares, the days-to-cover ratio is currently 8.1 days. View Celcuity's Short Interest .

When is Celcuity's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our CELC earnings forecast .

How were Celcuity's earnings last quarter?

Celcuity Inc. (NASDAQ:CELC) released its earnings results on Monday, November, 13th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by $0.09. During the same period in the prior year, the firm earned ($0.75) EPS.

What other stocks do shareholders of Celcuity own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Celcuity investors own include Bank of Hawaii (BOH) , InterDigital (IDCC) , STAG Industrial (STAG) , Evoke Pharma (EVOK) , Amicus Therapeutics (FOLD) , Allena Pharmaceuticals (ALNA) , Genocea Biosciences (GNCA) , Idera Pharmaceuticals (IDRA) and Ovid Therapeutics (OVID) .

When did Celcuity IPO?

Celcuity (CELC) raised $18 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 2,000,000 shares at a price of $8.00-$10.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO.

How do I buy shares of Celcuity?

Shares of CELC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CELC

Celcuity (CELC) Stock Price, News & Analysis

→ The Next Nvidia? (From InvestorPlace) (Ad)

Free CELC Stock Alerts

$16.39

-0.62 (-3.64%)

(As of 04/18/2024 ET)

Compare

Today's Range: $16.31
▼
$16.99
50-Day Range: $14.35
▼
$21.60
52-Week Range: $8.39
▼
$22.19

Volume: 200,027 shs
Average Volume: 215,480 shs
Market Capitalization: $499.08 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $29.00

Get Celcuity alerts:

Celcuity MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 76.9% Upside
$29.00 Price Target
Short Interest: Healthy
6.11% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.69
Based on 4 Articles This Week
Insider Trading: Selling Shares
$4,952 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.93) to ($3.62) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.89 out of 5 stars

Medical Sector

371st out of 919 stocks

Medical Laboratories Industry

11th out of 19 stocks

3.5

Analyst's Opinion

Consensus Rating
Celcuity has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Celcuity has only been the subject of 4 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
6.11% of the outstanding shares of Celcuity have been sold short.
Short Interest Ratio / Days to Cover
Celcuity has a short interest ratio ("days to cover") of 8.1.
Change versus previous month
Short interest in Celcuity has recently decreased by 7.46%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Celcuity does not currently pay a dividend.
Dividend Growth
Celcuity does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CELC.

3.2

News and Social Media Coverage

News Sentiment
Celcuity has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Celcuity this week, compared to 1 article on an average week.
MarketBeat Follows
2 people have added Celcuity to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Celcuity insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,952.00 in company stock.
Percentage Held by Insiders
24.29% of the stock of Celcuity is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
63.33% of the stock of Celcuity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Celcuity are expected to decrease in the coming year, from ($2.93) to ($3.62) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Celcuity is -6.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Celcuity is -6.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Celcuity has a P/B Ratio of 2.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Celcuity Stock (NASDAQ:CELC)

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

CELC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CELC Stock News Headlines

April 14, 2024 | americanbankingnews.com

Celcuity (NASDAQ:CELC) Stock Rating Reaffirmed by Needham & Company LLC

April 4, 2024 | globenewswire.com

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 3, 2024 | msn.com

Celcuity (NASDAQ:CELC): A Biotech with Blockbuster Potential

April 3, 2024 | finance.yahoo.com

Celcuity Gains 12%, Insider Trades Reap Benefit

April 1, 2024 | finance.yahoo.com

Celcuity Inc. (NASDAQ:CELC) Q4 2023 Earnings Call Transcript

March 30, 2024 | msn.com

I Gave Birth At A US Hospital In 2023 — Let's Break Down My $65,000 Bill

March 30, 2024 | msn.com

One dead, another in ICU after drug overdose

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 29, 2024 | markets.businessinsider.com

Gedatolisib’s Promising Clinical Trial Performance and Market Potential Justify Buy Rating

March 28, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Celcuity (CELC), Cara Therapeutics (CARA)

March 28, 2024 | finance.yahoo.com

Q4 2023 Celcuity Inc Earnings Call

March 27, 2024 | finance.yahoo.com

Celcuity Inc (CELC) Reports Full Year 2023 Financial Results and Highlights Key Developments

March 27, 2024 | benzinga.com

Recap: Celcuity Q4 Earnings

March 27, 2024 | globenewswire.com

Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

March 20, 2024 | globenewswire.com

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call

March 15, 2024 | finance.yahoo.com

CELC Apr 2024 20.000 call

March 6, 2024 | globenewswire.com

Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024

February 28, 2024 | finance.yahoo.com

Celcuity to Participate in Cowen’s 44th Annual Health Care Conference

February 28, 2024 | globenewswire.com

Celcuity to Participate in Cowen's 44th Annual Health Care Conference

February 25, 2024 | msn.com

Celcuity (CELC) Price Target Increased by 12.99% to 27.95

February 23, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND) and Celcuity (CELC)

February 23, 2024 | msn.com

Stifel Initiates Coverage of Celcuity (CELC) with Buy Recommendation

February 22, 2024 | msn.com

Stifel starts Celcuity at buy, sees gedatolisib as potential blockbuster

February 22, 2024 | finance.yahoo.com

Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer

February 20, 2024 | finanznachrichten.de

Celcuity Inc.: Celcuity Appoints Eldon Mayer as Chief Commercial Officer

February 20, 2024 | finance.yahoo.com

Celcuity Appoints Eldon Mayer as Chief Commercial Officer

See More Headlines

Receive CELC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celcuity and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/13/2023
Today: 4/18/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Medical laboratories
Sub-Industry: N/A
Current Symbol: NASDAQ:CELC
CUSIP: N/A
CIK: 1603454
Web: www.celcuity.com
Phone: (763) 392-0767
Fax: N/A
Employees: 55
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $29.00
High Stock Price Target: $40.00
Low Stock Price Target: $24.00
Potential Upside/Downside: +76.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.69)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-63,780,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -54.74%
Return on Assets: -39.13%

Debt

Debt-to-Equity Ratio: 0.26
Current Ratio: 13.43
Quick Ratio: 13.43

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.48 per share
Price / Book: 2.99

Miscellaneous

Outstanding Shares: 30,450,000
Free Float: 23,056,000
Market Cap: $499.08 million
Optionable: Optionable
Beta: 0.78

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Brian F. Sullivan (Age 62)
Co-Founder, Chairman & CEO
Comp: $478.12k
Dr. Lance G. Laing Ph.D. (Age 62)
Co-Founder, Chief Science Officer, VP, Secretary & Director
Comp: $389.55k
Ms. Vicky Hahne (Age 58)
Chief Financial Officer
Comp: $281.59k
Dr. John R. MacDonald Dabt (Age 69)
Ph., Ph.D., Senior Vice President of R&D
Ms. Sheri Smith
Acting Head of Clinical Operations
Mr. Igor Gorbatchevsky M.D.
Chief Medical Officer
Mr. Eldon C. Mayer III (Age 63)
M.B.A., Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CELC Stock Analysis - Frequently Asked Questions

Should I buy or sell Celcuity stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celcuity in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CELC shares.
View CELC analyst ratings or view top-rated stocks.
What is Celcuity's stock price target for 2024?: 4 Wall Street analysts have issued 1-year target prices for Celcuity's shares. Their CELC share price targets range from $24.00 to $40.00. On average, they anticipate the company's stock price to reach $29.00 in the next twelve months. This suggests a possible upside of 76.9% from the stock's current price.
View analysts price targets for CELC or view top-rated stocks among Wall Street analysts.
How have CELC shares performed in 2024?: Celcuity's stock was trading at $14.57 at the beginning of 2024. Since then, CELC stock has increased by 12.5% and is now trading at $16.39.
View the best growth stocks for 2024 here.
Are investors shorting Celcuity?: Celcuity saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 1,860,000 shares, a decrease of 7.5% from the March 15th total of 2,010,000 shares. Based on an average daily volume of 230,800 shares, the days-to-cover ratio is currently 8.1 days.
View Celcuity's Short Interest.
When is Celcuity's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our CELC earnings forecast.

How were Celcuity's earnings last quarter?: Celcuity Inc. (NASDAQ:CELC) released its earnings results on Monday, November, 13th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by $0.09. During the same period in the prior year, the firm earned ($0.75) EPS.
What other stocks do shareholders of Celcuity own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Celcuity investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Evoke Pharma (EVOK), Amicus Therapeutics (FOLD), Allena Pharmaceuticals (ALNA), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA) and Ovid Therapeutics (OVID).
When did Celcuity IPO?: Celcuity (CELC) raised $18 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 2,000,000 shares at a price of $8.00-$10.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO.
How do I buy shares of Celcuity?: Shares of CELC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CELC) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Celcuity (CELC) Stock Price, News & Analysis

Celcuity MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Celcuity Stock (NASDAQ:CELC)

CELC Stock Price History

CELC Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

CELC Stock Analysis - Frequently Asked Questions

Overall MarketRank^™